Valuation: Mirum Pharmaceuticals, Inc.

Market Cap 5.68B 103B 5.02B 4.75B 4.3B 8.07B 545B 8.15B 56.94B 21.94B 279B 21.34B 20.88B 896B P/E 2026 *
-5.79x
P/E 2027 * -119x
Enterprise Value 5.87B 106B 5.18B 4.9B 4.44B 8.33B 563B 8.41B 58.75B 22.64B 287B 22.02B 21.54B 925B EV / Sales 2026 *
8.42x
EV / Sales 2027 * 7.03x
Free-Float
98.34%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Mirum Pharmaceuticals, Inc.

3 years 448.5
Extreme 448.5
1,256.12
5 years 373.88
Extreme 373.88
1,256.12
10 years 291.23
Extreme 291.23
1,256.12
Manager TitleAgeSince
Chief Executive Officer 47 2019-03-20
Director of Finance/CFO 66 2023-09-10
President 48 2024-01-15
Director TitleAgeSince
Chairman 73 2019-03-20
Director/Board Member 55 2018-11-06
Director/Board Member 47 2018-10-31
Change 5-day change 1-year change 3-year change Capi.($)
+32.43%-.--% - - 5.68B
-0.01%+1.24%+63.06%+120.55% 1,056B
-1.61%-0.60%+47.32%+71.79% 645B
-1.12%-0.72%+17.98%+76.63% 465B
+0.94%-3.41%+34.97%+41.42% 335B
+1.15%+3.61%+21.69%+30.49% 275B
+0.36%-0.05%+11.11%+13.46% 255B
+1.32%+3.27%+54.63%+57.63% 229B
-0.61%-0.91%+34.33%+101.87% 188B
-0.01%-0.75%-27.36%-60.69% 169B
Average +3.61%-0.12%+28.64%+50.35% 401.8B
Weighted average by Cap. +0.44%+0.24%+38.80%+71.07%

Financials

2026 *2027 *
Net sales 697M 12.58B 615M 582M 527M 989M 66.84B 999M 6.98B 2.69B 34.13B 2.62B 2.56B 110B 820M 14.8B 723M 684M 621M 1.16B 78.64B 1.17B 8.21B 3.16B 40.16B 3.08B 3.01B 129B
Net income -926M -16.72B -817M -773M -701M -1.31B -88.86B -1.33B -9.28B -3.57B -45.38B -3.48B -3.4B -146B -26.73M -483M -23.59M -22.32M -20.24M -37.95M -2.57B -38.32M -268M -103M -1.31B -100M -98.19M -4.22B
Net Debt 181M 3.27B 160M 151M 137M 257M 17.36B 259M 1.81B 699M 8.87B 679M 665M 28.53B 74.95M 1.35B 66.15M 62.58M 56.76M 106M 7.19B 107M 751M 289M 3.67B 281M 275M 11.82B
Logo Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Employees
433
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
87.54USD
Average target price
145.79USD
Spread / Average Target
+66.54%

Quarterly revenue - Rate of surprise